Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 5/2018

01-10-2018 | Case Report

Autochthonous acute hepatitis E: treatment with sofosbuvir and ribavirin

Authors: Elisa Biliotti, Cristiana Franchi, Martina Spaziante, Anna Rosa Garbuglia, Lorenzo Volpicelli, Donatella Palazzo, Maurizio De Angelis, Rozenn Esvan, Gloria Taliani

Published in: Infection | Issue 5/2018

Login to get access

Abstract

Introduction

Hepatitis E virus (HEV) is an emerging cause of autochthonous-acute-hepatitis and acute-on-chronic-liver-failure in western countries. Treatment is not routinely used, despite ribavirin has a good antiviral effect. In vitro sofosbuvir inhibits HEV replication, but clinical data are lacking.

Case report

We report a case of acute-on-chronic-liver-failure due to HEV treated with sofosbuvir and ribavirin. The treatment was capable of rapidly inducing both HCV and HEV viral suppression.

Conclusion

In conclusion, although more data are required before firm conclusions could be drawn, the combination of sofosbuvir and ribavirin in not immunosuppressed patients with acute hepatitis E may be able to clear HEV infection.
Literature
1.
Peron JM, Abravanel F, Guillaume M, Gérolami R, Nana J, Anty R, et al. Treatment of autochthonous acute hepatitis E with short-term ribavirin: a multicenter retrospective study. Liver Int. 2016;36:328–33.CrossRefPubMed
2.
Riveiro-Barciela M, Mınguez B, Girones R, Rodriguez-Frías F, Quer J, Buti M. Phylogenetic demonstration of hepatitis E infection transmitted by pork meat ingestion. J Clin Gastroenterol. 2015;49:165–8.CrossRefPubMed
3.
Péron JM, Bureau C, Poirson H, Mansuy JM, Alric L, Selves J, et al. Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy. J Viral Hepat. 2007;14:298–303.CrossRefPubMed
4.
Kamar N, Izopet J, Tripon S, Bismuth M, Hillaire S, Dumortier J, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med. 2014;370:1111–20.CrossRefPubMed
5.
Dao Thi VL, Debing Y, Wu X, Rice CM, Neyts J, Moradpour D, et al. Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology. 2016;150:82–5.CrossRefPubMed
6.
Garbuglia AR, Scognamiglio P, Petrosillo N, Mastroianni CM, Sordillo P, Gentile D, et al. Hepatitis E virus genotype 4 outbreak, Italy, 2011. Emerg Infect Dis. 2013;19:110–4.CrossRefPubMedPubMedCentral
7.
Donnelly MC, Imlach SN, Abravanel F, Ramalingam S, Johannessen I, Petrik J, et al. Sofosbuvir and daclatasvir anti-viral therapy fails to clear HEV viremia and restore reactive T cells in a HEV/HCV co-infected liver transplant recipient. Gastroenterology. 2017;152:300–1.CrossRefPubMed
8.
Van der Valk M, Zaaijer HL, Kater AP, Schinkel J. Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection. J Hepatol. 2017;66:242–3.CrossRefPubMed
9.
Todesco E, Demeret S, Calin R, Roque-Afonso AM, Thibault V, Mallet V, et al. Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of sofosbuvir-ribavirin. AIDS. 2017;31:1346–8.CrossRefPubMed
10.
Pavio N, Doceul V, Bagdassarian E, Johne R. Recent knowledge on hepatitis E virus in Suidae reservoirs and transmission routes to human. Vet Res. 2017;48:78.CrossRefPubMedPubMedCentral
Metadata
Title
Autochthonous acute hepatitis E: treatment with sofosbuvir and ribavirin
Authors
Elisa Biliotti
Cristiana Franchi
Martina Spaziante
Anna Rosa Garbuglia
Lorenzo Volpicelli
Donatella Palazzo
Maurizio De Angelis
Rozenn Esvan
Gloria Taliani
Publication date
01-10-2018
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 5/2018
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-018-1168-7

Other articles of this Issue 5/2018

Infection 5/2018 Go to the issue

Case Report

Mycotic aneurysm caused by Clostridium septicum in a patient with colorectal cancer

Original Paper

Native vertebral osteomyelitis in aged patients: distinctive features. An observational cohort study

Correction

Correction to: A challenging case of carbapenemase-producing Klebsiella pneumoniae septic thrombophlebitis and right mural endocarditis successfully treated with ceftazidime/avibactam

Original Paper

Onset of symptoms, diagnostic confirmation, and occurrence of multiple infective foci in patients with Staphylococcus aureus bloodstream infection: a look into the order of events and potential clinical implications

Original Paper

Diabetes was the only comorbid condition associated with mortality of invasive pneumococcal infection in ICU patients: a multicenter observational study from the Outcomerea research group

Original Paper

Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits